Navigation Links
Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma
Date:10/15/2008

Zevalin(R) First-Line Indolent (FIT) Phase III Clinical Trial results

published in Journal of Clinical Oncology

SEATTLE, Oct. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology has published the results of the First-line Indolent Trial (FIT) demonstrating that use of Zevalin(R)([90Y]-ibritumomab tiuxetan) in consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma provided important patient benefits including a significant improvement in progression free survival. A companion editorial discussed the growing evidence for the efficacy of radioimmunotherapy (RIT) in B-cell lymphomas. Cell Therapeutics has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for use of Zevalin in first-line consolidation therapy based on the FIT data.

Oliver W. Press, M.D., Ph.D., Member of the Fred Hutchinson Cancer Research Center and Professor at the University of Washington, commented in his editorial that the studies "confirm and extend prior data demonstrating the tremendous potential of RIT in the treatment of B-cell NHL at diagnosis and after relapse at both conventional and myeloablative doses. Despite the overwhelming body of evidence, however, RIT remains underused in the United States and other countries. The reasons for this underuse have been widely debated but seem to be related, at least partially, to logistic issues involved in the transfer of care from the hematologist/oncologist to the nuclear medicine physician, concerns about inadequate reimbursement by Medicare for RIT, and exaggerated emphasis on delayed effects such as marrow damage and secondary malignancies. It is hoped that studies such as those in this issue would encourage wider appreciation and use of RIT."

"We couldn't agree more with Dr. Press' comments about
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing
2. Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
3. Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
4. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
5. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
6. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
7. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
8. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
9. Hospital Launches Landmark Emergency Medicine Project
10. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
11. Viatronix V3D-Colon Utilized in Another Landmark Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  Aethlon Medical, Inc. ... devices to address infectious disease, cancer and other ... Research Projects Agency (DARPA) has informed the Company ... proceed with year four of a five-year $5.9 ... September 30, 2011 under DARPA,s Dialysis-Like Therapeutics (DLT) ...
(Date:9/22/2014)... , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... quarter and fiscal 2014 ended July 31, 2014 on Monday, ... call to discuss the results at 11:00 AM ET. Participating ... Chairman; Andrew A. Krakauer , President and CEO; ... Craig A. Sheldon , Senior Vice President, CFO and Treasurer; ...
(Date:9/22/2014)... SAN FRANCISCO , Sept. 22, 2014  Sutro ... FierceBiotech as one of 2014,s Fierce 15 ... promising private biotechnology companies in the industry.  ... A-list group of backers as well as industry partners ... developing antibody-drug conjugates and bispecifics," says John Carroll ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3
... March 22 Cambrex Corporation (NYSE: ... a privately held company that is a leader in ... Wiesbaden, Germany and offers cost effective customized ... pharmaceutical industry, with the ability to utilize its tool ...
... Inc. (OTC Bulletin Board: GOVX), a biotechnology company that is developing and testing innovative HIV/AIDS vaccines, has engaged The Investor Relations Group ("IRG"), ... , ... , ... ...
Cached Medicine Technology:Cambrex Acquires IEP GmbH 2Cambrex Acquires IEP GmbH 3GeoVax Labs Engages The Investor Relations Group 2GeoVax Labs Engages The Investor Relations Group 3GeoVax Labs Engages The Investor Relations Group 4
(Date:9/22/2014)... Alan Mozes HealthDay Reporter ... take note: Many American parents are aware of online physician-rating ... a pediatrician for their children, according to a new national ... than 1,600 parents -- further suggest that negative online ratings ... doctor has been recommended by a neighbor. Conversely, a ...
(Date:9/22/2014)... Asians living in Canada have a higher rate of ... with while people, McMaster researchers have found. , ... Medical Association Journal (CMAJ Open) and may be ... fastest-growing ethnic groups in the country is the more ... comprising about three percent of the population. They include ...
(Date:9/22/2014)... Kessler researchers have published a pilot study showing ... in people with multiple sclerosis (MS). Improvements ... stress, and pain. "Development and effectiveness of ... MS: Description and outcomes" was epublished ahead of ... Journal of MS Care (doi: 10.7224/1537-2073.2013-045). The ...
(Date:9/22/2014)... new prescription devices approved by the U.S. Food and ... with migraine headaches who don,t tolerate migraine medications well, ... the Cefaly -- is designed to prevent migraines, while ... to be used when migraines first start, according to ... for alternative migraine treatments. Because these devices aren,t ingested ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Severe weather can occur ... time. That’s why, as part of National Preparedness Month, Amica ... your family prepare for the unexpected:, , Build ... as nonperishable food and one gallon of water per person per ... Create an evacuation plan that includes pets so your family knows ...
Breaking Medicine News(10 mins):Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Amica Shares Tips for National Preparedness Month 2
... N.J., Feb. 17 Novo Nordisk, a global healthcare ... of Andy Ajello as vice president for National Diabetes ... Executive Team and will report directly to Jerzy Gruhn, ... recently the associate vice president of Diabetes Sales for ...
... Little known language in the economic stimulus ... efforts by nonprofit hospitals - resulting in fewer ... of essential health care services provided to the ... the 11th hour thanks to the efforts of ...
... CryoLife, Inc. (NYSE: CRY ), a,biomaterials, medical ... Food and Drug Administration (FDA) has cleared a new ... The new labeling claim,relates to reducing a component of ... CryoValve SG pulmonary human heart ...
... Year,s Most Common ClaimsBREA, Calif., Feb. 17 Not ... and cuddly. Take ear infections, for example, or skin ... (VPI), the nation,s oldest and largest provider of pet ... to find the year,s most common pet maladies. The ...
... "natural" ingredients should be regarded as a driver for ... 17 According to Kline & Company,s study ... 2008: U.S. and Europe , botanicals consumption is growing ... average growth of 5.4%. The increased use of botanicals ...
... DIEGO, Feb. 17 Tracon Pharmaceuticals, a biotechnology company ... announced today that its three clinical stage cancer therapeutics ... 100th Annual Meeting of the American Association for Cancer ... program targets a unique pathway with the potential for ...
Cached Medicine News:Health News:Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts 2Health News:Philanthropic Fundraising Activities in Stimulus Bill Preserved Thanks to the Efforts of the Association for Healthcare Philanthropy 2Health News:FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve 2Health News:FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve 3Health News:Sick as a Dog: Pets' Top Medical Conditions of 2008 2Health News:Sick as a Dog: Pets' Top Medical Conditions of 2008 3Health News:Desire for Performance Coupled With Natural Ingredients Boosts Botanical Actives Consumption in Personal Care 2Health News:Desire for Performance Coupled With Natural Ingredients Boosts Botanical Actives Consumption in Personal Care 3Health News:Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009 2Health News:Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: